ADMA LAWSUIT: ADMA Biologics, Inc. Sued For Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses

ADMA Biologics has been sued for securities fraud for allegedly misleading investors about revenue growth through a channel-stuffing scheme involving its ASCENIV product and failing to disclose a related-party distribution relationship. A Culper Research report revealed the growth was driven by excess inventory rather than genuine demand, causing the stock to plummet from $13.59 to $8.29 per share. Investors who purchased shares between August 9, 2024, and March 25, 2026, may be eligible to recover losses.